Biovision ExCap - Experience Captialisation of Biovision’s environmental-friendly Malaria and African animal trypanosomiasis control projects from 2005-2020 for greater impact

At the core of Biovision’s engagement are agroecological transformations including innovative community-led interventions for the control of vector-borne human, animal and plant diseases. The current mandate focuses on programmes for Malaria and AAT control with a flagship character that had been implemented by Biovision and their strong partner networks in Ethiopia and Kenya from 2005-2019. The overall goal of the mandate is to conduct an experience capitalization providing recommendations for Biovision’s future engagement led by its new 2021-2024 strategy, which particularly advocates for applying ecological innovations such as Integrated Vector Management (IVM) to improve detection and control of zoonotic and vector-borne diseases by applying a One Health approach.

The mandate is structured into four phases. During Phase 1, the primary task will be an assessment of Biovision’s engagement in Malaria and AAT control. Two major outputs shall be developed based on this review: a) an overview of Malaria and tsetse fly control activities supported through Biovision financing in the past and to date; and b) a synthesis of the key learnings, an overview of the projects set-up, and an insight in each intervention’s performance in different contexts / conditions. Hereby, the review will be focusing particularly on a strategic level to serve as guiding document for discussions to align Biovision’s portfolio with the four objectives as defined in the new strategy 2021 – 2024. The review will be based on available internal project documents and external evaluation reports.

In Phase 2, learning cases will be prepared in close collaboration with in-country stakeholders. These will address the following four key topics: a) uptake, ownership and eventual expansion of malaria and tsetse fly control activities initially funded by Biovision and later taken up by other actors; b) a description of the type and role of evidence used for informing decision- and / or policy-making at national and global level, as well as its effects; c) the identification of key scientific gaps for an adequate evidence base; and d) explore new and promising approaches or tools as part of IVM. Meeting counterparts will include Biovision’s implementing partners and collaborators at icipe and KEMRI, community leaders and groups, local, regional national policy stakeholders, relevant technical experts in the field of IVM, as well as private sector actors such as from the production side of IVM technologies.

Phase 3 involves the mapping of actors and IVM initiatives and therewith complements the insights gained during the previous phases. Specifically, the aim is to identify and map key stakeholders in environmental-friendly IVM globally and particularly in Kenya. Additionally, other currently funded, tested and implemented IVM techniques and strategies shall be documented, and their performance and results assessed by reviewing the generated evidence and impacts, if available.

Phase 4 is the consolidation phase and includes the preparation of the experience capitalization report and other products including for example a policy brief or an article. A fundamental part of the report is the development of recommendations based on the findings from the previous phases regarding next steps for Biovision, to further strengthen their engagement and investment in environmental-friendly IVM, and the potential for new partnerships and collaborations.

Contact

Helena Greter

Helena Greter, PhD
Project Officer / Manager, Wissenschaftliche Mitarbeitende/Post-Doc (SHIS 530)

+41 61 284 87 30
helena.greterswisstph.ch

Project Facts